Charles River Laboratories
CRL
621 hedge funds and large institutions have $10.1B invested in Charles River Laboratories in 2023 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 230 increasing their positions, 219 reducing their positions, and 62 closing their positions.
29% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 62
1% more funds holding
Funds holding: 612 → 621 (+9)
1.1% more ownership
Funds ownership: 99.94% → 101.05% (+1.1%)
5% more repeat investments, than reductions
Existing positions increased: 230 | Existing positions reduced: 219
6% less capital invested
Capital invested by funds: $10.7B → $10.1B (-$599M)
35% less call options, than puts
Call options by funds: $40.7M | Put options by funds: $62.7M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Meritage Group
San Francisco,
California
|
+$181M |
| 2 |
SCA
Southpoint Capital Advisors
New York
|
+$82.1M |
| 3 |
MBI
Montrusco Bolton Investments
Montreal,
Quebec, Canada
|
+$46.3M |
| 4 |
KBC Group
Brussels,
Belgium
|
+$43.8M |
| 5 |
AC
Armistice Capital
New York
|
+$32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$167M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$66.2M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$62.6M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$42.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$39.7M |
CRL Hedge Fund Activity: Q3 2023 in Review
621 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2023, worth a combined $10.1B — down 5.6% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new CRL positions and 62 closed out — a net gain of 18 holders — while 230 added to existing stakes and 219 trimmed.
The largest buyer was Meritage Group, opening a new position worth an estimated $181M. The largest seller was T. Rowe Price Associates, cutting an estimated $167M.
- 621 institutional investors held Charles River Laboratories (CRL) as of Q3 2023, up from 612 in Q2 2023.
- Funds reported $10.1B of Charles River Laboratories stock for Q3 2023, down 5.6% quarter-over-quarter.
- 80 funds opened new Charles River Laboratories positions in Q3 2023 and 62 closed out, a net change of +18 holders.
- The largest Charles River Laboratories buyer in Q3 2023 was Meritage Group, an estimated $181M added.
- The largest Charles River Laboratories seller in Q3 2023 was T. Rowe Price Associates, an estimated $167M sold.
Based on aggregated 13F filings for Q3 2023.